Vote Scores
Filings read through

Catalyst Pharmaceuticals, Inc.: how funds voted at the meeting of 21 May 2024

Meeting
Season
year to 30 June 2024
Filers reporting
414
Ballot items
6

414 filers on Form N-PX reported votes at the Catalyst Pharmaceuticals, Inc. meeting of 21 May 2024. The records fall into 6 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2024. The latest season on file is the year to 30 June 2026. The page of Catalyst Pharmaceuticals, Inc. has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2024. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    7 nominees. 95.3% of the reported votes are for. 14 filers withheld from or voted against at least one nominee.

    2,061 vote records from 151 filers. 5 of the 151 filers that marked the item voted against management.

    • Positions of 43 fund families
    • For 42
    • Against 1
    • Against management 1
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    719 vote records from 409 filers. 34 of the 396 filers that marked the item voted against management. 13 filers gave no management mark.

    2 filers reported share counts too large for the holding. The share split leaves those figures out; the counts of filers keep them. The rule

    • Positions of 48 fund families
    • For 46
    • Against 2
    • Against management 2
  3. Item 3: Audit-related items (auditor ratification)

    293 vote records from 149 filers. 1 of the 149 filers that marked the item voted against management.

    • Positions of 43 fund families
    • For 43
  4. Item 4: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    297 vote records from 152 filers. 5 of the 152 filers that marked the item voted against management.

    • Positions of 43 fund families
    • For 41
    • Against 2
    • Against management 2
  5. Item 5: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    265 vote records from 133 filers. 131 of the 133 filers that marked the item voted against management.

    • Positions of 40 fund families
    • Against 40
    • Against management 40
  6. Item 6: OTHER: management items

    The company's items in this category are shown together, because filers word and number them differently.

    29 vote records from 19 filers. 14 of the 19 filers that marked the item voted against management.

    • Positions of 4 fund families
    • For 2
    • Against 2
    • Against management 2

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Catalyst Pharmaceuticals, Inc., meeting of 21 May 2024Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
AllianceBernsteinForNo report
AllspringForFor
American CenturyAgainst, against managementFor
BairdForNo report
BlackRock and iSharesForFor
BNY MellonForFor
Brighthouse FundsForFor
Charles SchwabForFor
Columbia ThreadneedleAgainst, against managementFor
DimensionalForFor
DWSForFor
EquitableForFor
Federated HermesForFor
FidelityForFor
First TrustForFor
Franklin TempletonForFor
Global XForFor
Goldman SachsForFor
Guggenheim and RydexForFor
InvescoForFor
J.P. MorganForFor
Jackson National fundsForFor
Janus HendersonForFor
John Hancock and ManulifeForFor
Lincoln FinancialForFor
MassMutualForNo report
MFSForFor
Morgan Stanley, Eaton Vance and CalvertForFor
NationwideForFor
Natixis and Loomis SaylesForNo report
Neuberger BermanForNo report
Northern Trust and FlexSharesForFor
Nuveen and TIAAForFor
Pacific Life fundsForFor
PGIM and PrudentialForFor
PrincipalForFor
ProShares and ProFundsForFor
Russell InvestmentsForFor
SEIForFor
State Street and SPDRForFor
T. Rowe PriceForFor
ThriventForFor
TransamericaForFor
VanguardForFor
Victory CapitalForFor
VirtusForFor
VoyaForFor
WisdomTreeForFor

Questions

How many filers reported votes at the Catalyst Pharmaceuticals, Inc. meeting?
414 Form N-PX filers reported votes at the meeting of 21 May 2024. On say-on-pay, 34 of 396 filers that marked the item voted against management (8.6%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Catalyst Pharmaceuticals, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Catalyst Pharmaceuticals, Inc. with a meeting date within three days of 21 May 2024. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .